Advarra
↗Columbia, USA
Advarra is a market-leading provider of regulatory review solutions and clinical research technology for sponsors, CROs, and research sites. The company is the largest integrated provider of Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) services, supporting thousands of institutions and academic medical centers worldwide.
Beyond its core regulatory oversight services, Advarra offers a comprehensive suite of technology solutions—including Clinical Trial Management Systems (CTMS), eRegulatory management, and AI-driven study design tools—designed to streamline clinical trial operations, enhance data integrity, and accelerate research timelines.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$500M
Founded:2017
Ownership:private
Status:operating
FUNDING
Investors:Blackstone Group, CPP Investment Board, Genstar Capital Partners, Linden Capital Partners
0
CORPORATE STRUCTURE
Parent Company:Blackstone Group / CPP Investment Board
Acquired By:Blackstone Group and CPP Investment Board (2022-08-01)
Subsidiaries:Longboat, IntegReview, YourEncore
Key Partnerships:IQVIA (Collaboration on COVID-19 vaccine trials), Parexel (IRB/IBC services)
COMPETITION
Position:Leader
Competitors:WCG, BRANY, BioSafety Corporation
LEADERSHIP
Key Executives:
Gadi Saarony - CEO
LINKS
Website:advarra.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Advarra and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Advarra. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.